849 assets in Breast Cancer

Therapeutic assets addressing Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Bl-M07D1 Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	CCC (54)
Co-Methylcobinamide Dihydrogen Phosphate (Ester) Inner Salt 3'-Ester With 5,6-Dimethyl-1-.Alpha.-D-Ribofuranosyl-1H-Benzimidazole-.Kappa.N(Sip 3) Breast Cancer	Peking University Cancer Hospital & Institute	P4	CCC (54)
Deoxyadrenaline Breast Cancer	Fujian Medical University Union Hospital	P4	CCC (54)
Fluorizoparib Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	CCC (54)
Fluzoparib Breast Cancer	Fudan University	P3	CCC (54)
Gedatolisib Breast Cancer	Celcuity Inc	P3	CCC (54)
Hemay022 Breast Cancer	Tianjin Hemay Pharmaceutical Co., Ltd	P3	CCC (54)
Herzuma Breast Cancer	National Cancer Institute (NCI)	P2	CCC (54)
Hrs-6209 Breast Cancer	Atridia Pty Ltd.	P2	CCC (54)
Ibrutinib Breast Cancer	The Netherlands Cancer Institute	P2	CCC (54)
Imlunestrant Breast Cancer	Fudan University	P2	CCC (54)
Jskn003 Breast Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	CCC (54)
Luvixasertib Breast Cancer	Canadian Cancer Trials Group	P2	CCC (54)
Monosialotetrahexosylganglioside Breast Cancer	Alliance for Clinical Trials in Oncology	P3	CCC (54)
Muamycin Breast Cancer	UNICANCER	P3	CCC (54)
Palazestrant Breast Cancer	Olema Pharmaceuticals, Inc.	P3	CCC (54)
pf-07248144 Breast Cancer	Pfizer	P3	CCC (54)
Revaree Plus Breast Cancer	Memorial Sloan Kettering Cancer Center	P4	CCC (54)
Rintatolimod Breast Cancer	Roswell Park Cancer Institute	P1/2	CCC (54)
Rocuronium Ion Breast Cancer	Jun Zhang	P4	CCC (54)
Sacubitril Valsartan Breast Cancer	Silesian Centre for Heart Diseases	P4	CCC (54)
Saruparib Breast Cancer	AstraZeneca	P3	CCC (54)
sim0270 Breast Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P3	CCC (54)
Sitagliptin Breast Cancer	Tanta University	P4	CCC (54)
Suvorexant Breast Cancer	Medical University of South Carolina	P4	CCC (54)
Sv-Br-1-Gm Breast Cancer	BriaCell Therapeutics Corporation	P3	CCC (54)
sys6010 Breast Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P3	CCC (54)
Theprubicin Breast Cancer	Chinese Academy of Medical Sciences	P4	CCC (54)
Trastuzumab Mafodotin Breast Cancer	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P3	CCC (54)
Trastuzumab Pamirtecan Breast Cancer	DualityBio Inc.	P3	CCC (54)
u3-1402 Breast Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P2	CCC (54)
Utomilumab Breast Cancer	Laura Huppert, MD, BA	P2	CCC (54)
Viscum Album Breast Cancer	Ilsan Cha hospital	P4	CCC (54)
[99mtc]tc-db8 Breast Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P2	CCC (53)
[99mTc]Tc-ZHER2:4107 Breast Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P2	CCC (53)
Avapritinib Breast Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Brc-001 Breast Cancer	City of Hope Medical Center	P2	CCC (53)
Catequentinib Breast Cancer	Zhejiang Cancer Hospital	P2	CCC (53)
Cetirizine Breast Cancer	Maryam Lustberg	P3	CCC (53)
Cik Cells Breast Cancer	Fuda Cancer Hospital, Guangzhou	P2	CCC (53)
Colesevelam Breast Cancer	Spanish Breast Cancer Research Group	P2	CCC (53)
Decitabine Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Dota-Pabza-Dig-Dphe-Gln-Trp-Ala-Val-Gly-His-Nhch(Ch2Ch(Ch3)2)2 Breast Cancer	Novartis Pharmaceuticals	P2	CCC (53)
Entrectinib Breast Cancer	OHSU Knight Cancer Institute	P2	CCC (53)
Fexagratinib Breast Cancer	UNICANCER	P2	CCC (53)
Fezolinetant Breast Cancer	Yale University	P2	CCC (53)
FFNP Breast Cancer	University of Wisconsin, Madison	P2	CCC (53)
Gadopiclenol Breast Cancer	University of Zurich	P2	CCC (53)
Gallium-68 Labelled Fap-2286 Breast Cancer	Odense University Hospital	P2	CCC (53)
Ganetespib Breast Cancer	University of Chicago	P2	CCC (53)

Showing 251 to 300 of 849 assets

PreviousPage 6 of 17Next